StreetInsider.com News Articles

Form 4 PTC THERAPEUTICS, INC. For: Aug 26 Filed by: SCHMERTZLER MICHAEL

Fri, 28 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260828/26999118.html

Form 4 PTC THERAPEUTICS, INC. For: Aug 26 Filed by: SCHMERTZLER MICHAEL

Fri, 28 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260828/26999118.html

Form 8-K PTC THERAPEUTICS, INC. For: Aug 25

Fri, 28 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260828/26997887.html

Form 8-K PTC THERAPEUTICS, INC. For: Aug 25

Fri, 28 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260828/26997887.html

PTC Therapeutics to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 08:00:00 -0400

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTC Therapeutics to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 08:00:00 -0400

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTC Therapeutics to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 08:00:00 -0400

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTC Therapeutics to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 08:00:00 -0400

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

Form 144/A PTC THERAPEUTICS, INC. Filed by: SCHMERTZLER MICHAEL

Tue, 25 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260825/26975041.html

Form 144/A PTC THERAPEUTICS, INC. Filed by: SCHMERTZLER MICHAEL

Tue, 25 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260825/26975041.html

PTC Therapeutics to present Sephience PKU data at SSIEM 2026

Mon, 24 Aug 2026 08:01:39 -0400

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that 17 abstracts and presentations on Sephience (sepiapterin) are scheduled for the 2026 Society for the Study of Inborn Errors of Metabolism Annual Symposium in Helsinki, Finland, from Aug. 25-28.

The presentations include data from clinical trials and real-world studies on Sephience, which is approved in the United States, the European Union, Japan, and other countries for the treatment of phenylketonuria (PKU) in patients one month of age and older.

Key data highlights from a company press release include findings from the AMPLIPHY study showing that participants who switched to Sephience from sapropterin achieved a 100%

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety P

Mon, 24 Aug 2026 08:00:00 -0400

– 17 abstracts and presentations planned at SSIEM Symposium –

– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels –

– Continued evidence of meaningful benefit across all patient subgroups –

WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety P

Mon, 24 Aug 2026 08:00:00 -0400

– 17 abstracts and presentations planned at SSIEM Symposium –

– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels –

– Continued evidence of meaningful benefit across all patient subgroups –

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety P

Mon, 24 Aug 2026 08:00:00 -0400

– 17 abstracts and presentations planned at SSIEM Symposium –

– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels –

– Continued evidence of meaningful benefit across all patient subgroups –

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety P

Mon, 24 Aug 2026 08:00:00 -0400

– 17 abstracts and presentations planned at SSIEM Symposium –

– Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels –

– Continued evidence of meaningful benefit across all patient subgroups –

Form 4 PTC THERAPEUTICS, INC. For: Aug 19 Filed by: SCHMERTZLER MICHAEL

Fri, 21 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260821/26962492.html

Form 4 PTC THERAPEUTICS, INC. For: Aug 19 Filed by: SCHMERTZLER MICHAEL

Fri, 21 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260821/26962492.html

Form 4 PTC THERAPEUTICS, INC. For: Aug 17 Filed by: Boulding Mark Elliott

Wed, 19 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260819/26951174.html

Form 4 PTC THERAPEUTICS, INC. For: Aug 17 Filed by: Boulding Mark Elliott

Wed, 19 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260819/26951174.html

Form 144 PTC THERAPEUTICS, INC. Filed by: SCHMERTZLER MICHAEL

Wed, 19 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260819/26950859.html

Form 144 PTC THERAPEUTICS, INC. Filed by: SCHMERTZLER MICHAEL

Wed, 19 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260819/26950859.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Mon, 17 Aug 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260817/26936562.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Mon, 17 Aug 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260817/26936562.html

PTC Therapeutics (PTCT) PT Raised to $122 at Barclays

Fri, 14 Aug 2026 04:21:01 -0400

Barclays analyst Eliana Merle raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $122.00 (from $120.00) while maintaining a Overweight rating.

PTC Therapeutics (PTCT) PT Raised to $109 at Wells Fargo

Thu, 13 Aug 2026 08:42:19 -0400

Wells Fargo analyst Benjamin Burnett raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $109.00 (from $106.00) while maintaining a Overweight rating.